By Christian Moess Laursen


AstraZeneca's rare-disease unit Alexion has completed a purchase and license agreement for early-stage rare-disease gene therapy portfolio from Pfizer for a total consideration of $1 billion, the Anglo-Swedish pharma giant said Wednesday.

"These new resources will build on the combined capabilities of Alexion and AstraZeneca in genomic medicine, with the objective to develop new genetic therapies with improved safety and efficacy profiles," it said.

The consideration includes tiered royalties on sales. Several of the Pfizer employees associated with the portfolio will join Alexion as employees, it said.


Write to Christian Moess Laursen at


(END) Dow Jones Newswires

September 20, 2023 02:29 ET (06:29 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 11 2023 まで 12 2023 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 12 2022 まで 12 2023 Pfizerのチャートをもっと見るにはこちらをクリック